Calls to action on lung cancer management and research.

Détails

Ressource 1Télécharger: 39002167_BIB_554AFB6D6C3A.pdf (16793.84 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_554AFB6D6C3A
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Calls to action on lung cancer management and research.
Périodique
The oncologist
Auteur⸱e⸱s
Meyer M.L., Hirsch F.R., Bunn P.A., Ujhazy P., Fredrickson D., Berg C.D., Carbone D.P., Halmos B., Singh H., Borghaei H., Ferris A., Langer C., Dacic S., Mok T.S., Peters S., Johnson B.E.
ISSN
1549-490X (Electronic)
ISSN-L
1083-7159
Statut éditorial
Publié
Date de publication
06/12/2024
Peer-reviewed
Oui
Volume
29
Numéro
12
Pages
e1634-e1645
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Lung cancer, the leading cause of cancer-related deaths globally, remains a pressing health issue despite significant medical advances. The New York Lung Cancer Foundation brought together experts from academia, the pharmaceutical and biotech industries as well as organizational leaders and patient advocates, to thoroughly examine the current state of lung cancer diagnosis, treatment, and research. The goal was to identify areas where our understanding is incomplete and to develop collaborative public health and scientific strategies to generate better patient outcomes, as highlighted in our "Calls to Action." The consortium prioritized 8 different calls to action. These include (1) develop strategies to cure more patients with early-stage lung cancer, (2) investigate carcinogenesis leading to lung cancers in patients without a history of smoking, (3) harness precision medicine for disease interception and prevention, (4) implement solutions to deliver prevention measures and effective therapies to individuals in under-resourced countries, (5) facilitate collaborations with industry to collect and share data and samples, (6) create and maintain open access to big data repositories, (7) develop new immunotherapeutic agents for lung cancer treatment and prevention, and (8) invest in research in both the academic and community settings. These calls to action provide guidance to representatives from academia, the pharmaceutical and biotech industries, organizational and regulatory leaders, and patient advocates to guide ongoing and planned initiatives.
Mots-clé
Humans, Lung Neoplasms/therapy, Biomedical Research, Precision Medicine/methods, biomarkers, immunotherapy, non–small cell lung cancer, screening, small cell lung cancer, smoking cessation
Pubmed
Web of science
Open Access
Oui
Création de la notice
19/07/2024 10:25
Dernière modification de la notice
21/01/2025 7:19
Données d'usage